Quetiapine vademecum Review article
Article Sidebar
Published:
Jun 30, 2013
Keywords:
quetiapine, indications, doses, off-label use
Main Article Content
Abstract
Quetiapine is an atypical antipsychotic administered for the treatment of schizophrenia, bipolar disorder, major depressive disorder, reactive disorder (e.g. PTSD), anxiety (e.g. GAD), behavioral disorders, behavioral and psychological symptoms of dementia, insomnia, alcohol dependence, Tourette syndrome, and many other disorders. Quetiapine is being widely used for both off-label and officially registered treatments.
Article Details
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Leonhauser M. Antipsychotics: multiple indications help drive growth. PM 360 Market Watch 2012 [online: www.PM360online.com].
2. Kusum M. Quetiapine utilization by prescriber specialty. Diagnosis associated with the use of quetiapine. Department of Health and Human Services, Public Health Service, Food and Drug Administration. Raport z 05.12.2011.
3. Lieberman JA. The use antipsychotics in primary care. Primary Care Companion. J Clin Psychiatry 2003; 5 (supl 3): 3-8.
4. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatric Services 2009; 60(9): 1175-1181.
5. Rowe DL. Off-label prescription of Quetiapine in psychiatric disorders. Expert Rev Neurother 2007; 7(7): 841-852.
6. Łoza B. Pozarejestracyjne zastosowania kwetiapiny. Neuropsychiatria. Przegląd Kliniczny 2013; 4(1): 44-50.
7. Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Reviews, No. 43. Agency for Healthcare Research and Quality; Rockville (MD) 2011.
8. Walton SM, Schumack GT, Ky-Van L, Alexander GC, Meltzer D, Stafford R. Developing evidence-based research priorities for off-label drug use. Agency for Healthcare Research and Quality, Rockville, MD, 2009.
9. Monasterio E, McKean A. Off-label use of atypical antipsychotic medications in Canterbury, New Zealand. N Z Med J 2011; 124(1336): 24-29.
10. Buna M. Pozarejestracyjne zastosowanie kwetiapiny w leczeniu bezsenności. Neuropsychiatria. Przegląd Kliniczny 2012; 4(4): 178-181.
11. Busko M. Quetiapine Widely Used Off-Label in Psychiatric In patients in Single-Site Study. Medscape 24.05.2007 [online: http://www.medscape.com/viewarticle/557216].
12. Kozma CM, Engelhart LM, Long S, Greenspan A, Mahmoud R, Baser O. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotics. International College of Geriatric Psychoneuropharmacology 2003.
13. Powers RE. A Short Practical Guide for Psychotropic Medications in Dementia Patients. Bureau of Geriatric Psychiatry; Alabama 2008.
14. Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson’s disease. Ther Adv Neurol Disord 2010; 3(6): 339-350.
15. Dolder CR, McKinsey J. Quetiapine for sleep in patients with dementia. Consult Pharm 2010; 25(10): 676-679.
16. Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, doubleblind, placebo-controlled study. Curr Alzheimer Res 2007; 4(1): 81-93.
17. Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar In patients with coexisting alcohol dependence. Alcohol Clin Exp Res 2010; 34(10): 1822-1831.
18. Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 2012; 36(3): 406-416.
19. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol 2012; Jun 28 [online: doi: 10.1111/j.1369-1600.2012.00461.x]. 20. Montgomery S et al. A randomised, placebo-controlled study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
21. Bauer M et al. Results from a phase III study of extended release quetiapine fumarate (quetiapine XR) as add-on to antidepressants in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
22. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011; 31(4): 418-428.
23. Rowe DL. Off-label prescription of Quetiapine in psychiatric disorders. Expert Rev Neurother 2007; 7(7): 841-852.
24. Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics 2009; 50(2): 159-161.
25. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. J Clin Sleep Med 2008; 4(5): 487-504.
26. Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother 2012; 46(5): 718-722.
27. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette’s disorder. J Ch Adol Psychopharm 2003; 13(3): 295-299.
28. van den Eynde F, De Saedeleer S, Naudts K, Day J, Vogels C, van Heeringen C, Audenaert K. Quetiapine treatment and improved cognitive functioning in borderline personality disorder. Hum Psychopharmacol 2009; 24(8): 646-649.
29. Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, Thas O, van Heeringen C, Audenaert K. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol 2008; 28(2): 147-155.
30. Adityanjee, Romine A, Brown E, Thuras P, Lee S, Schulz SC. Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry 2008; 20(4): 219-226.
31. Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1): 158-163.
32. Roepke S, Merkl A, Dams A, Ziegenhorn A, Anghelescu IG, Heuser I, Lammers CH. Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: an open label trial. Pharmacopsychiatry 2008; 41(5): 176-181.
33. Rihmer Z. Antidepressive efficacy of quetiapine XR in unipolar major depression - the role of early onset of action and sleepimproving effect in decreasing suicide risk. Neuropsychopharmacol Hung 2009; 11(4): 211-215.
34. Tilghman A, McGarry B. Medicating the military. Army Times 17.03.2010 [online: http://www.armytimes.com/article/20100317/NEWS/3170315/Medicating-the-military].
35. Edwards J. How Seroquel, a risky antipsychotic, became a “general purpose” mental health drug. Citizens Commission on Human Rights International. 27.05.2011 [online: http://www.cchrint.org/2011/05/27/how-seroquel/].
36. Altamura AC, Moliterno D, Paletta S, Buoli M, Dell’osso B, Mauri MC, Bareggi SR. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Clin Drug Investig 2012; 32(3): 213-219.
2. Kusum M. Quetiapine utilization by prescriber specialty. Diagnosis associated with the use of quetiapine. Department of Health and Human Services, Public Health Service, Food and Drug Administration. Raport z 05.12.2011.
3. Lieberman JA. The use antipsychotics in primary care. Primary Care Companion. J Clin Psychiatry 2003; 5 (supl 3): 3-8.
4. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatric Services 2009; 60(9): 1175-1181.
5. Rowe DL. Off-label prescription of Quetiapine in psychiatric disorders. Expert Rev Neurother 2007; 7(7): 841-852.
6. Łoza B. Pozarejestracyjne zastosowania kwetiapiny. Neuropsychiatria. Przegląd Kliniczny 2013; 4(1): 44-50.
7. Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Reviews, No. 43. Agency for Healthcare Research and Quality; Rockville (MD) 2011.
8. Walton SM, Schumack GT, Ky-Van L, Alexander GC, Meltzer D, Stafford R. Developing evidence-based research priorities for off-label drug use. Agency for Healthcare Research and Quality, Rockville, MD, 2009.
9. Monasterio E, McKean A. Off-label use of atypical antipsychotic medications in Canterbury, New Zealand. N Z Med J 2011; 124(1336): 24-29.
10. Buna M. Pozarejestracyjne zastosowanie kwetiapiny w leczeniu bezsenności. Neuropsychiatria. Przegląd Kliniczny 2012; 4(4): 178-181.
11. Busko M. Quetiapine Widely Used Off-Label in Psychiatric In patients in Single-Site Study. Medscape 24.05.2007 [online: http://www.medscape.com/viewarticle/557216].
12. Kozma CM, Engelhart LM, Long S, Greenspan A, Mahmoud R, Baser O. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotics. International College of Geriatric Psychoneuropharmacology 2003.
13. Powers RE. A Short Practical Guide for Psychotropic Medications in Dementia Patients. Bureau of Geriatric Psychiatry; Alabama 2008.
14. Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson’s disease. Ther Adv Neurol Disord 2010; 3(6): 339-350.
15. Dolder CR, McKinsey J. Quetiapine for sleep in patients with dementia. Consult Pharm 2010; 25(10): 676-679.
16. Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, doubleblind, placebo-controlled study. Curr Alzheimer Res 2007; 4(1): 81-93.
17. Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar In patients with coexisting alcohol dependence. Alcohol Clin Exp Res 2010; 34(10): 1822-1831.
18. Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 2012; 36(3): 406-416.
19. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol 2012; Jun 28 [online: doi: 10.1111/j.1369-1600.2012.00461.x]. 20. Montgomery S et al. A randomised, placebo-controlled study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
21. Bauer M et al. Results from a phase III study of extended release quetiapine fumarate (quetiapine XR) as add-on to antidepressants in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
22. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011; 31(4): 418-428.
23. Rowe DL. Off-label prescription of Quetiapine in psychiatric disorders. Expert Rev Neurother 2007; 7(7): 841-852.
24. Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics 2009; 50(2): 159-161.
25. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. J Clin Sleep Med 2008; 4(5): 487-504.
26. Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother 2012; 46(5): 718-722.
27. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette’s disorder. J Ch Adol Psychopharm 2003; 13(3): 295-299.
28. van den Eynde F, De Saedeleer S, Naudts K, Day J, Vogels C, van Heeringen C, Audenaert K. Quetiapine treatment and improved cognitive functioning in borderline personality disorder. Hum Psychopharmacol 2009; 24(8): 646-649.
29. Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, Thas O, van Heeringen C, Audenaert K. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol 2008; 28(2): 147-155.
30. Adityanjee, Romine A, Brown E, Thuras P, Lee S, Schulz SC. Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry 2008; 20(4): 219-226.
31. Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1): 158-163.
32. Roepke S, Merkl A, Dams A, Ziegenhorn A, Anghelescu IG, Heuser I, Lammers CH. Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: an open label trial. Pharmacopsychiatry 2008; 41(5): 176-181.
33. Rihmer Z. Antidepressive efficacy of quetiapine XR in unipolar major depression - the role of early onset of action and sleepimproving effect in decreasing suicide risk. Neuropsychopharmacol Hung 2009; 11(4): 211-215.
34. Tilghman A, McGarry B. Medicating the military. Army Times 17.03.2010 [online: http://www.armytimes.com/article/20100317/NEWS/3170315/Medicating-the-military].
35. Edwards J. How Seroquel, a risky antipsychotic, became a “general purpose” mental health drug. Citizens Commission on Human Rights International. 27.05.2011 [online: http://www.cchrint.org/2011/05/27/how-seroquel/].
36. Altamura AC, Moliterno D, Paletta S, Buoli M, Dell’osso B, Mauri MC, Bareggi SR. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Clin Drug Investig 2012; 32(3): 213-219.